|
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Associations were found between toxicities and gene variants (P<0.05), including neutropenia with ABCB1 (rs1045642) and SLC0B3 (rs4149117 and rs7311358); and diarrhoea with CYP2C9 (rs1057910), CYP2C19 (rs3758581), UGT1A6 (rs4124874) and SLC22A1 (rs72552763).
|
28817838 |
2017 |
|
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In addition, a statistically significant association was found among neutropenia (absolute neutrophil count<500) and variant allele carriers of ABCB1 rs1045642 (OR=5.174; 95% CI: 1.674; 15.989) and ABCB1 rs1128503 (OR=3.364; 95% CI: 1.257; 9.004), respectively.
|
25007187 |
2014 |
|
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
On evaluating higher order gene-gene interaction models by MDR analysis, CYP3A5*3; ABCB11236C>T and ABCB1 2677G>T/A; ABCB1 3435C>T and CYP1B1*3 showed significant association with treatment response, grade 2-4 anemia and dose delay/reduction due to neutropenia (P=0.024, P=0.004, P=0.026), respectively.
|
24704000 |
2014 |
|
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
C3435T polymorphisms of ABCB1 might be able to predict severe amrubicin-induced neutropenia.
|
24982363 |
2014 |
|
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
With regard to ABCB1 3435 C>T, ABCB1 3435 T/T had significantly higher risks of neutropenia (P = 0.015).
|
22271208 |
2012 |
|
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
CYP2C8*3 and the ABCB1 SNPs C1236T, G2677T/A, and C3435T were not statistically significantly correlated to overall survival, sensoric neuropathy, and neutropenia in 119 patients treated for ovarian cancer with paclitaxel/carboplatin.
|
21327421 |
2011 |
|
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Statistical associations were observed, suggesting a lower risk of neutropenia (p = 0.013) and hand-foot syndrome (HFS; p = 0.027) for the carriers of T variation for rs1128503 in capecitabine-treated patients, carriers of T variation for rs1045642 treated with capecitabine had a lower risk of HFS (p = 0.033), while those treated with 5-FU had a higher risk of diarrhea (p = 0.035), and carriers of T variation for rs2032592 treated with capecitabine were at less risk of developing HFS (p = 0.033).
|
21142915 |
2010 |
|
rs1045642
|
|
|
0.080 |
GeneticVariation |
BEFREE |
PG analysis showed that ABCB1 (C3435T)T/T (membrane transport) was associated with IP-related diarrhea; UGT1A1 (G-3156A)A/A (drug metabolism) was associated with IP-related neutropenia.
|
19349543 |
2009 |
|
rs2032582
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Delayed time to neutropenia recovery was observed with ABCB1 rs2032582 variant (p = .047).
|
27701910 |
2017 |
|
rs2032582
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Meta-analysis showed an decreased risk of irinotecan-induced neutropenia in patients expressing ABCB1 2677G>T/G (odds ratio [OR]: 0.24; 95% CI: 0.1-0.59; p = 0.002) but increased risk for ABCC2 3972T>T (OR: 1.67; 95% CI: 1.01-2.74; p = 0.04).
|
27269636 |
2016 |
|
rs2032582
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The multivariate logistic regression analysis revealed that the ABCB1 2677G>T/A polymorphism was a strong predictor of grade 3 or greater neutropenia (odds ratio: 3.76; 95% confidence interval: 1.44-9.81; p = 0.007).
|
25989890 |
2015 |
|
rs2032582
|
|
|
0.050 |
GeneticVariation |
BEFREE |
On evaluating higher order gene-gene interaction models by MDR analysis, CYP3A5*3; ABCB11236C>T and ABCB1 2677G>T/A; ABCB1 3435C>T and CYP1B1*3 showed significant association with treatment response, grade 2-4 anemia and dose delay/reduction due to neutropenia (P=0.024, P=0.004, P=0.026), respectively.
|
24704000 |
2014 |
|
rs2032582
|
|
|
0.050 |
GeneticVariation |
BEFREE |
In toxicity, the 2677G/T or A was associated with grade 4 neutropenia.
|
17534875 |
2007 |
|
rs1801160
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Univariate analysis allowed the selection of c.1905+1G>A, c.2194G>A and c.2846A>T alleles as significantly associated with gastrointestinal and hematological ADRs (p < 0.05), while the c.496A>G variant showed a positive trend of association with neutropenia (p = 0.06).
|
30723313 |
2019 |
|
rs1801160
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The additional DPYD polymorphisms could enhance the prevention of fluoropyrimidine toxicity. c.2194G>A is the most frequent polymorphism and it was found to be associated with neutropenia.
|
30858516 |
2019 |
|
rs1801160
|
|
|
0.040 |
GeneticVariation |
BEFREE |
*6 rs1801160 (FDR<0.0001), and *2A rs3918290 (FDR=0.0004) variant alleles were significantly associated with time to neutropenia.
|
29065426 |
2017 |
|
rs1801160
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Moreover, we identified a strong association of V732I with leucopenia (OR = 8.17; 95%CI 2.44 - 27.31) and neutropenia (OR=2.78; 95% CI 1.03-7.51).
|
19473056 |
2009 |
|
rs2072671
|
|
|
0.030 |
GeneticVariation |
BEFREE |
This is the first genetic analysis of gemcitabine-induced neutropenia using a competing risk model in a prospective randomized clinical study has proposed a potentially novel mechanism of the protective effect of the CDA rs2072671 variant.Further confirmation is needed.
|
30889042 |
2019 |
|
rs2814778
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Individuals homozygous for the C allele at rs2814778 were significantly more likely to develop neutropenia and have to stop clozapine treatment (OR = 20.4, P = 3.44 × 10<sup>-7</sup>).
|
30647433 |
2019 |
|
rs67376798
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Univariate analysis allowed the selection of c.1905+1G>A, c.2194G>A and c.2846A>T alleles as significantly associated with gastrointestinal and hematological ADRs (p < 0.05), while the c.496A>G variant showed a positive trend of association with neutropenia (p = 0.06).
|
30723313 |
2019 |
|
rs67376798
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Two rare DPYD variants were associated with increased toxicity (Asp949Val with neutropenia, nausea and vomiting, diarrhoea and infection; IVS14+1G>A with lethargy, diarrhoea, stomatitis, hand-foot syndrome and infection; all ORs > 3).
|
30114658 |
2018 |
|
rs2814778
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Healthy individuals of African ancestry have neutropenia that has been linked with the variant rs2814778(G) of the gene encoding atypical chemokine receptor 1 (ACKR1).
|
28553950 |
2017 |
|
rs67376798
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The DPYD*2A variant statistically significantly associated with the specific AEs nausea/vomiting (P = .007) and neutropenia (P < .001), whereas D949V statistically significantly associated with dehydration (P = .02), diarrhea (P = .003), leukopenia (P = .002), neutropenia (P < .001), and thrombocytopenia (P < .001).
|
25381393 |
2014 |
|
rs2072671
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Our study suggests that CDA 79A>C mutation might be a potential risk factor of gemcitabine-induced neutropenia toxicity.
|
22546611 |
2012 |
|
rs2072671
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Patients carrying the nonsynonymous CDA SNP 79A >C (CDA*2) had a 21% lower gemcitabine clearance as compared to wild-type patients (outcomes and complications.0.0009), but the risk for chemotherapy-associated neutropenia (61% vs. 32%, P = 0.07) and severe neutropenia (17% vs. 5%, P = 0.26) was not significantly higher.
|
21590444 |
2012 |